drugset / Trial / NCT00849381

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand

NCT00849381

Phase 3 Completed 1239 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).

Timeline

Start
2009-04
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cervarix Vaccine Intramuscular